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StatinsNon-alcoholic fatty liver disease (NAFLD) is characterized by intra-hepatic fat accumulation and mechanisms
involved in its pathogenesis are not fully explained. Lysosomal Acid Lipase (LAL) is a key enzyme in lipid
metabolism. We investigated its activity in patients with fatty liver.
LAL activity (nmol/spot/h) was measured in 100 adult healthy subjects (HS) and in 240 NAFLD patients. A sub-
analysis on 35 patients with biopsy-proven non-alcoholic steatohepatitis (NASH) was performed.
Median LAL activitywas 1.15 (0.95–1.72) inHS. Itwas signiﬁcantly reduced inNAFLD [0.78 (0.61–1.01), p b 0.001
vs. HS]. A further reduction was observed in the subgroup of NASH [0.67 (0.51–0.77), p b 0.001 vs. HS]. Patients
with LAL activity belowmedian had higher values of serum total cholesterol (p b 0.05) and LDL-c (p b 0.05), and
increased serum liver enzymes (ALT, p b 0.001; AST, p b 0.01; GGT, p b 0.01). At multivariable logistic regression
analysis, factors associated with LAL activity belowmedian were ALT (OR: 1.018, 95% CI 1.004–1.032, p= 0.011)
and metabolic syndrome (OR: 2.551, 95% CI 1.241–5.245, p = 0.011), whilst statin use predicted a better LAL
function (OR: 0.464, 95% CI 0.248–0.866, p = 0.016).
Our ﬁndings suggest a strong association between impaired LAL activity and NAFLD. A better knowledge of the
role of LAL may provide new insights in NAFLD pathogenesis.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is characterized by intra-
hepatic fatty acid (lipid) accumulation, affecting a growing number of
people worldwide (Vernon et al., 2011; Bellentani et al., 2000). NAFLD
includes a wide spectrum of diseases extending from simple fatty liver
to non-alcoholic steatohepatitis (NASH) and cirrhosis (Farrell and
Larter, 2006), and, before long,will become themain cause of liver failure
in the next future (Kemmer et al., 2013).
Many pathophysiological mechanisms have been associated to
NAFLD, including insulin resistance (Angelico et al., 2005), dyslipidaemia
(Corey et al., 2015), oxidative imbalance (Del Ben et al., 2014a), gut
microbiota (Compare et al., 2012) alteration and genetic factors (Del
Ben et al., 2014b). Several therapeutic intervention have been proposedUmberto I, Viale del Policlinico
gelico).
. This is an open access article under(Pastori et al., 2015a; Del Ben et al., 2014c; Angelico et al., 2007;
Chalasani et al., 2012).
In the liver, hyperinsulinemia is responsible for impaired mitochon-
drial oxidation of fatty acids, which consequently accumulate and
are then partly metabolised by peroxisomes and microsomes with the
production of reactive oxygen species and lipid peroxidation (Del Ben
et al., 2014a).
Only a minority of patients with simple steatosis will develop NASH,
and no reliable biomarkers of disease progression are available (Sanyal
et al., 2015).
Lysosomal Acid Lipase (LAL) is a hydrolase that plays a key role in
intra-cellular cholesterol trafﬁcking. Inside the lysosomes, LAL hydroly-
ses triglycerides and cholesterol esters derived from plasma lipoproteins
via LDL-receptor pathway (Fasano et al., 2012). A reduced LAL activity
promotes an increased cholesterol ester storage in lysosomes, as ob-
served in two genetic diseases, namely Wolman and Cholesterol Ester
Storage Disease (CESD) (Fasano et al., 2012), which are characterized
by total or sub-total LAL deﬁciency (Thelwall et al., 2013; Pisciotta et al.,
2009; Fouchier and Defesche, 2013). These conditions are associated
with severe liver steatosis and rapid liver failure (Bernstein et al., 2013;
Reiner et al., 2014; Reynolds, 2013). Furthermore, LAL supplementationthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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steatosis (Valayannopoulos et al., 2014).
Ourhypothesiswas that a reductionof LALactivitymaycontribute to in-
tracellular fatty acid accumulation in adult NAFLD. Thus, we measured the
activity of LAL in a cohort of adult patients affectedbyNAFLD, andwe inves-
tigated factors associated with reduced LAL activity.
2. Methods
2.1. Study Design
The study was performed in 240 consecutive patients with ultrasonog-
raphy (US) evidence of fatty liver, referring to the Day Service of Internal
Medicine of the Policlinico Umberto I University Hospital in Rome.
Inclusion criteria were: no history of excessive alcohol consumption
deﬁned as a mean daily intake of alcohol N 20 g; no history of Hepatitis
C–B viruses infection with negative tests for the presence of hepatitis B
surface antigen and antibody to hepatitis C virus; no history for other
chronic liver diseases; and no therapy with drugs known to promote
liver steatosis (e.g., amiodarone). Subjects underwent routine biochem-
ical evaluation including alanine aminotransferase (ALT), aspartate
aminotransferase (AST), γ-glutamyltransferase (GGT), fasting total
and HDL-cholesterol, triglycerides, glucose and insulin. Waist circum-
ference, height and weight were recorded and body mass index (BMI)
was calculated.
The homeostasis model of insulin resistance (HOMA-IR) was used
as a measure of IR (Matthews et al., 1985). Metabolic syndrome was
diagnosed according to the ATP III modiﬁed criteria (Anon., 2001). The
presence of diabetes and arterial hypertension was deﬁned according
to international guidelines (Authors et al., 2013; Mancia et al., 2013).
All patients provided signed informed consent before the study. The
study was approved by the local ethical board of Sapienza University
of Rome (ref. n° 2277/2011), and conducted according to the ethical
principles embodied in the Declaration of Helsinki. Funding source:
none.
2.2. Ultrasonography Evaluation of Fatty Liver
Liver US scanning was performed to assess the degree of steatosis.
All US were performed by the same operator who was blinded to labo-
ratory values using a GE Vivid S6 apparatus equipped with a convex
3.5 MHz probe. Liver steatosis was deﬁned according to Hamaguchi
criteria based on the presence of abnormally intense, high level echoes
arising from the hepatic parenchyma, liver–kidney difference in echo
amplitude, echo penetration into deep portion of the liver and clarity
of liver blood vessel structure (Saverymuttu et al., 1986; Hamaguchi
et al., 2007).
2.3. Liver Biopsy
Percutaneous liver biopsy was performed under US guide in 35 of
the above fatty liver patients with clinical suspicion of NASH by their
treating hepatologists. The decision to perform the biopsy was individ-
ualized and based on a persistent elevation of serum alanine amino-
transferase levels (N1.5 upper normal values) for more than 6 months
and the presence of bright liver at US scan. A single operator performed
ultrasound-guided liver biopsies. Pathologist who examined biopsies
specimen was blinded to patients' identity or clinical information.
NASH diagnosis was deﬁned using standard criteria (Sanyal et al.,
2011). All patients who underwent liver biopsy satisﬁed histological
criteria for NASH.
2.4. Lysosomal Acid Lipase Activity Assay
All blood samples were taken after a 12-hour fast. LAL-activity was
dosed with dried blood spot (DBS) technique using the inhibitorsLalistat 2. Ethylene-diamine-tetra acetic acid (EDTA) blood, obtained
by venepuncture, was spotted on to ﬁlter paper (Whatman grade
903 Schleicher & Schuell) and allowed to dry overnight at room
temperature. Samples were stored double-bagged with desiccant at
−20 °C and analysed within 2 weeks of storage. Uninhibited and
inhibited with Lalistat 2 activities were dosed. LAL activity was
determined by subtracting activity in the inhibited reaction from un-
inhibited reaction (total lipase) and expressed as nmol/spot/h of 4
MU (methylumbelliferone) (Hamilton et al., 2012). DBS tests were
performed in Bambino Gesù Hospital in Rome. Physicians analysing
LAL activity were unaware of clinical and biochemical characteristics
of any enrolled patient. Inter and intra-assay variations were 2.4%
and 2.3%, respectively.
To establish a normal value of LAL activity in adults, we performed
DBS tests in 100 normal weight healthy subjects (HS), matched for
age and sex with NAFLD patients. HS were not taking any drug or sup-
plement before the blood sample collection, had no ultrasound evidence
of fatty liver disease and did not suffer for any acute or chronic disease.
2.5. Statistical Analysis
Distribution of continuous variables was tested using a Kolmogorov–
Smirnov test. Data are expressed as the mean ± standard deviation for
normally distributed variables and as median followed by the 25th and
75th percentiles in parenthesis for non-normally distributed data.
Group comparisons were performed by unpaired Student's t-test and by
Mann–Whitney or Kruskal–Wallis test for non-normally distributed
variables.
Proportions and categorical variableswere tested by the χ2 test or by
the 2-tailed Fisher's exact.
For the analyses, we divided the cohort according to the median
value of LAL activity. We performed a multivariable logistic regression
analysis with LAL activity below median as dependent variable. After
testing for collinearity, the following covariates were used for the
model: female gender, body mass index, alanine aminotransferase
(ALT), statin therapy, anti-hypertensive drug, triglycerides, gamma-
glutamyl transpeptidase (γ-gt), and metabolic syndrome. Moreover, a
multivariable logistic regression analysis was performed to evaluate
the independent predictors of the presence of NASH after controlling
for gender, age, platelets, metabolic syndrome, homeostasis model
assessment-insulin resistance (HOMA-IR), serum total cholesterol,
triglycerides, γ-GT, ALT and LAL activity below median. All tests are
two-tailed, and a p b 0.05was considered as cut-off for statistical signif-
icance. Statistical analysis was performed by using the SPSS statistical
software version 20.0 for Windows (SPSS, Inc., Chicago. Illinois).
3. Results
3.1. LAL Activity in Healthy Subjects
Median blood LAL activity in 100 HSwas 1.15 (IQR 0.95–1.72) nmol/
spot/h; no difference between males (n = 55) and females (n = 45)
[1.08 (0.94–1.70) vs. 1.17 (0.96–1.74) p = 0.486] was found. HS group
had mean age of 53.0 ± 11.3 years; LAL activity was not correlated
with age (rs =−0.53, p = 0.590).
3.2. Analysis of LAL Activity in NAFLD Patients
Clinical and biochemical characteristics of 240 NAFLD patients are
listed in Table 1. Mean age was 55.4 ± 11.0 years; 60.4% were men.
LAL activity was signiﬁcantly reduced in patients with NAFLD, as
compared to those without [1.15 (0.94–1.72) vs. 0.78 (0.61–1.01)
nmol/spot/h, p b 0.001].
To investigate factors associatedwith reduced LAL activity, we divided
NAFLD patients in two groups according to the median value of LAL
(0.78 nmol/spot/h, Table 2).
Table 1
Characteristics of population.
NAFLD patients (N = 240)
Age (years) 55.4 ± 11.0
Male gender (%) 60.4
Body mass index (kg/m2) 30.5 ± 4.7
Waist circumference (cm)a 106.0 (101.0–113.8)
Diabetes mellitus (%) 31.9
Coronary heart disease (%) 6.8
Metabolic syndrome (%) 70.5
Statin users (%) 35.7
Total cholesterol (mg/dl) 198.3 ± 38.8
LDL cholesterol (mg/dl) 117.5 ± 33.0
HDL cholesterol (mg/dl) 48.4 ± 15.6
Triglycerides (mg/dl)a 146.5 (105.5–187.5)
ALT (U/l)a 30.0 (21.0–44.0)
AST (U/l)a 22.0 (18.0–32.0)
GGT (U/l)a 28.5 (18.0–43.5)
Glycaemia (mg/dl)a 90.0 (100.0–109.0)
Insulin (mU/l)a 14.3 (10.6–20.2)
HOMA-IRa 3.7 (2.6–5.6)
Creatinine (mg/dl)a 0.9 (0.8–1.0)
ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl
transpeptidase; HDL: high-density lipoprotein; HOMA IR: homeostasis model assessment-
insulin resistance; LDL: low-density lipoprotein.
a Data expressed as median and interquartile range.
Fig. 1. Lysosomal Acid Lipase activity in healthy subjects (HS), non-alcoholic fatty liver
disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
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had higher values of serum total cholesterol (p b 0.05) and LDL-c
(p b 0.05), and increased serum liver enzymes (ALT, p b 0.001; AST,
p b 0.01; GGT, p b 0.01). Moreover, in the same group of patients a
signiﬁcant lower prevalence of statin therapy (28% vs. 43.3%, p b 0.05)
was present. In addition, values of LAL activity were higher in patients
treated with statins compared to those without (Fig. 2).
At multivariable logistic regression analysis (Table 3), factors associ-
ated with impaired LAL activity (below median) were ALT (OR: 1.018,
95% CI 1.004–1.032, p = 0.011) and metabolic syndrome (OR: 2.551,
95% CI 1.241–5.245, p = 0.011), whilst statin use predicted a better
LAL function (OR: 0.464, 95% CI 0.248–0.866, p = 0.016).
3.3. LAL Activity and NASH
We also performed a sub-analysis in 35 patients with biopsy-proven
NASH.We observed a progressive decrease of LAL activity from patients
with simple steatosis [0.84 (0.62–1.08) nmol/spot/h, p b 0.001 vs. HS] toTable 2
Clinical and biochemical characteristics of patients with NAFLD above or below the median of
LAL activity
b0.78 nmol/spot/h (N = 120)
Age (years) 55.0 ± 11.0
Male gender (%) 63.4
Body mass index (kg/m2) 30.6 ± 4.7
Waist circumference (cm)a 106.0 (101.0–114.0)
Diabetes mellitus (%) 31.5
Coronary heart disease (%) 5.9
Metabolic syndrome (%) 76.1
Statin users (%) 28.0
Total cholesterol (mg/dl) 203.9 ± 40.8
LDL cholesterol (mg/dl) 122.4 ± 32.1
HDL cholesterol (mg/dl) 47.6 ± 17.7
Triglycerides (mg/dl)a 147.0 (112.0–177.0)
ALT (U/l)a 35.0 (24.0–53.0)
AST (U/l)a 23.0 (19.0–35.0)
γ-GT (U/l)a 32.0 (21.0–51.0)
Glycaemia (mg/dl) 103.0 (90.0–115.0)
Insulin (mU/l)a 15.2 (10.5–21.6)
HOMA-IRa 3.9 (2.5–5.8)
Creatinine (mg/dl)a 0.9 (0.8–1.0)
ALT: alanine aminotransferase; AST: aspartate aminotransferase; γ-GT: gamma-glutamyl trans
lin resistance; LDL: low-density lipoprotein.
a Data expressed as median and interquartile range.those with NASH [0.67 (0.51–0.77) nmol/spot/h, p b 0.001 vs. HS;
p b 0.001, among groups, Fig. 1].
To further investigate the association between NASH and low LAL
activity, a multiple logistic regression analysis showed a positive associ-
ation of LAL activity belowmedian (OR: 5.34, 95% CI 1.14–25.1, p b 0.05)
andALT values (OR: 1.11, 95% CI 1.07–1.16, p b 0.001)with the presence
of NASH (R2 = 0.43), after adjustment for potential confounders.
4. Discussion
This is the ﬁrst study reporting normal values of blood LAL activity in
healthy adult subjects; we found a median value of LAL activity of
1.15 nmol/spot/h, with no age and sex differences. We also investigated
LAL activity in a cohort of adult patients with NAFLD, and we found a
signiﬁcant reduction of LAL activity in NAFLD patients, compared to
healthy subjects. In particular, patients with NAFLD had a 27.0% reduc-
tion of LAL activity, which increased to 41.8% in the subgroup of patients
with biopsy proven NASH.
Patients with LAL activity below median had a signiﬁcant elevation
of serum liver enzymes and a worse lipid proﬁle (higher total and LDLLysosomal Acid Lipase (LAL) activity.
LAL activity
≥0.78 nmol/spot/h (N = 120)
p
56.0 ± 11.0 ns
59.5 ns
30.4 ± 4.7 ns
105.0 (100.0–113.0) ns
33.3 ns
7.6 ns
65.0 0.07
43.3 b0.05
192.8 ± 36.1 b0.05
112.7 ± 33.2 b0.05
49.2 ± 13.2 ns
146.0 (103.0–195.0) ns
26.0 (20.0–37.0) b0.01
21.0 (18.0–27.0) b0.01
25.0 (17.0–42.0) b0.01
97.0 (88.0–122.0) ns
13.7 (10.6–19.5) ns
3.3 (2.6–5.6) ns
0.9 (0.8–1.0) ns
peptidase; HDL: high-density lipoprotein; HOMA IR: homeostasis model assessment-insu-
Fig. 2. Lysosomal Acid Lipase activity in patients treated or not with statins.
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showing a similar lipid proﬁle with a polygenic hypercholesterolemia
phenotype in E8SJM LAL mutation carriers (Muntoni et al., 2013).
Of note, there are no data in the literature on the correlation
between circulating and hepatic LAL activity, and there is no general
agreement on whether a reduced blood LAL activity directly reﬂects
hepatic content of triglycerides and cholesterol esters (Puri et al.,
2007). In this context, Singh et al. (Singh et al., 2009) described a direct
involvement of autophagy and lysosomal pathway in the degradation of
intracellular lipid droplets in the liver. Thismay suggest that a reduction
of LAL activity might reduce droplets clearance and promote accumula-
tion of both esteriﬁed and unesteriﬁed cholesterol in hepatocytes.
LAL activity was inversely associated with ALT values and with the
presence of metabolic syndrome, whilst statin use was associated to
higher LAL values, at multivariable analysis. The inverse association
between LAL and ALT values may suggest that impaired LAL activity is
associated with liver damage. This ﬁnding is partially supported by the
further reduction of LAL activity observed in patients with biopsy-
proven NASH. However, whether low LAL activity contributes to liver
damage progression, or is itself a consequence of liver failure is still
unknown.
Of particular interest is the inverse association between metabolic
syndrome and LAL activity. This ﬁndingmay indicate a dual relationship
between the activity of LAL and the presence of metabolic risk factors.
Thus, we do not know if metabolic factors modulate LAL activity or if,
in turn, LAL activitymay contribute to the onset of dyslipidaemia typical
of metabolic syndrome. Nevertheless, measurement of LAL activity may
help to differentiate patients with a major LAL deﬁciency-related
NAFLD, from those with NAFLD due to metabolic syndrome.
The association between statin use and improved LAL function is an-
other interesting ﬁnding of the study. The use of statins is controversial
in patients with genetic deﬁciency of LAL, as in some CESD patients
dyslipidaemia persisted despite the lipid-lowering treatment, and liver
histology did not improve with statins (Reiner et al., 2014). Interesting-
ly, Fouchier and Defesche (Fouchier and Defesche, 2013) proposed aTable 3
Multivariate logistic regression analysis of factors associatedwith reduced Lysosomal Acid
Lipase activity (below median).
B SE Beta p value 95.0% C.I. for B
Age 0.005 0.014 1.005 0.744 0.977 1.034
Female gender −0.023 0.298 0.977 0.938 0.545 1.752
Body mass index −0.020 0.033 0.980 0.539 0.919 1.045
ALT 0.018 0.007 1.018 0.011 1.004 1.032
Statin therapy −0.768 0.318 0.464 0.016 0.248 0.866
Anti-hypertensive drugs −0.160 0.330 0.852 0.628 0.447 1.626
Triglycerides 0.000 0.001 1.000 0.630 0.998 1.001
γ-GT 0.003 0.003 1.003 0.293 0.998 1.008
Metabolic syndrome 0.937 0.368 2.551 0.011 1.241 5.245
ALT: alanine aminotransferase; γ-GT: gamma-glutamyl transpeptidase.combined approach with statins and LAL replacement therapy in
patients with mutations of Lysosomal Acid Lipase gene.
Our data suggest that in adult non-genetic LAL deﬁciency, statin
could modulate epigenetic expression of this enzyme or potentiate its
activity. However, it is unclear whether statins directly inﬂuence LAL
activity, perhaps as the result of a pleiotropic effect or, alternatively,
modulate it through their cholesterol-lowering activity. Nevertheless,
the causal relationship cannot be explored in the present study, and
an ad hoc interventional study is needed.
Finally, it has been recently reported that LAL released by macro-
phages in the extracellular space contributes to modiﬁcation of LDL
within the artery wall (Dubland and Francis, 2015). The Authors specu-
lated that early stage atherosclerosis may involve normal or increased
LAL activity, whereas later stages of atherosclerosis may have an
acquired dysfunction in LAL hydrolytic activity leading to lysosomal
cholesterol sequestration. Thus, LAL may represent one possible mech-
anism contributing to the accelerated atherosclerosis and increased
cardiovascular risk reported in patients with NAFLD (Sookoian and
Pirola, 2008; Pastori et al., 2015b). However, further research on this
issue is needed.
4.1. Limitations of the Study
A major limitation of this study is that it is a cross-sectional study,
and we therefore cannot establish a cause–effect relationship between
the reduction of LAL activity and the presence of NAFLD/NASH. The as-
sociation between LAL activity and NAFLD/NASH should be conﬁrmed
by a prospective study to evaluate the predictive value of LAL on the
progression of fatty liver disease. A further limitation is that this is a
single centre study performed in consecutive patients with US evidence
of fatty liver referred to a metabolic clinic.
5. Conclusions
In conclusion, our ﬁndings suggest a strong association between
impaired LAL activity and fatty liver disease. Our ﬁndings need to be
conﬁrmed in a larger sample of NASH patients, to establish if LAL
measurement may represent a non-invasive marker of NASH. A better
knowledge of the role of LALmay provide new insights in the pathogen-
esis and progression of NAFLD.
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NAFLD patients compared to healthy subjects, with a further reduction
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associated with ALT values and metabolic syndrome, and inversely
with statin use.
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